Synthetic biology startup StrainX Bioworks has secured $13 million in fresh funding from Prime Venture Partners and Leo Capital, marking a major milestone in its mission to revolutionize precision fermentation and bio‑manufacturing.
The Bengaluru‑based company plans to use the capital to scale manufacturing, expand research and development, and accelerate global commercialization of its sustainable biological solutions. StrainX operates at the intersection of biotechnology and sustainability, developing engineered microbial strains that enable the production of high‑value compounds without relying on traditional agriculture or petrochemical processes.
Founded by a team of scientists and entrepreneurs, StrainX aims to make bio‑manufacturing more efficient and accessible worldwide. The company’s technology leverages precision fermentation to produce ingredients for food, cosmetics, and pharmaceuticals, offering a cleaner and more scalable alternative to conventional production methods.
The latest investment underscores growing investor confidence in India’s emerging synthetic biology ecosystem, which is rapidly gaining traction as global industries seek greener, more cost‑effective solutions.
